Image Ben Hargreaves R&D R&D in 2023 sees focus return to oncology After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms. Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough. R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics. Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies. Load more results
R&D R&D in 2023 sees focus return to oncology After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms.
Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.
R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics.
Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.